OBJECTIVES: To evaluate the performance of a healthcare programme in early spondyloarthritis (SpA). METHODS: Based on previous analyses and expectations of a nominal group, the following were set: (1) minimum standards to create early SpA units; (2) standard operating procedures; and (3) eight performance indicators that can be measured in real time using a web-based platform. RESULTS: At the end of the evaluation of the programme the expected level of performance was achieved in three of the indicators: 'referral reliability' (standard (S) >50%, real value (RV) 92%), 'accessibility' (S >90%, RV=91%) and 'duration of first visit' (S >50%, RV=53%). The performance in the remaining indicators was inferior: 'success of referral criteria' (S >50%, RV=28%), 'clinical reports issued' (S >90%, RV=25%), 'feedback guarantee' (S >85%, RV=2%), 'missing data' (S <10%, RV=24%) and 'frequency of review' (S >90%, RV=84%). Explanations for the low performance are provided. CONCLUSIONS: It is possible to implement a large-scale programme that is measurable.
OBJECTIVES: To evaluate the performance of a healthcare programme in early spondyloarthritis (SpA). METHODS: Based on previous analyses and expectations of a nominal group, the following were set: (1) minimum standards to create early SpA units; (2) standard operating procedures; and (3) eight performance indicators that can be measured in real time using a web-based platform. RESULTS: At the end of the evaluation of the programme the expected level of performance was achieved in three of the indicators: 'referral reliability' (standard (S) >50%, real value (RV) 92%), 'accessibility' (S >90%, RV=91%) and 'duration of first visit' (S >50%, RV=53%). The performance in the remaining indicators was inferior: 'success of referral criteria' (S >50%, RV=28%), 'clinical reports issued' (S >90%, RV=25%), 'feedback guarantee' (S >85%, RV=2%), 'missing data' (S <10%, RV=24%) and 'frequency of review' (S >90%, RV=84%). Explanations for the low performance are provided. CONCLUSIONS: It is possible to implement a large-scale programme that is measurable.
Authors: Miguel Ángel Abad; Rafael Ariza Ariza; Juan José Aznar; Enrique Batlle; Emma Beltrán; Juan de Dios Cañete; Eugenio de Miguel; Alejandro Escudero; Cristina Fernández-Carballido; Jordi Gratacós; Estíbaliz Loza; Luis Francisco Linares; Carlos Montilla; Manuel Moreno Ramos; Juan Mulero; Rubén Queiro; Enrique Raya; Carlos Rodríguez Lozano; Jesús Rodríguez Moreno; Jesús Sanz; Lucía Silva-Fernández; Juan Carlos Torre Alonso; Pedro Zarco; José Luis Fernández-Sueiro; Xavier Juanola Journal: Rheumatol Int Date: 2014-01-04 Impact factor: 2.631
Authors: Jordi Gratacós; Jesús Luelmo; Jesús Rodríguez; Jaume Notario; Teresa Navío Marco; Pablo de la Cueva; Manel Pujol Busquets; Mercè García Font; Beatriz Joven; Raquel Rivera; Jose Luis Alvarez Vega; Antonio Javier Chaves Álvarez; Ricardo Sánchez Parera; Jose Carlos Ruiz Carrascosa; Fernando José Rodríguez Martínez; José Pardo Sánchez; Carlos Feced Olmos; Conrad Pujol; Eva Galindez; Silvia Pérez Barrio; Ana Urruticoechea Arana; Mercedes Hergueta; Pablo Coto; Rubén Queiro Journal: Rheumatol Int Date: 2018-02-07 Impact factor: 2.631
Authors: Victoria Navarro-Compán; Eugenio de Miguel; Désirée van der Heijde; Robert Landewé; Raquel Almodóvar; Carlos Montilla; Emma Beltrán; Pedro Zarco Journal: Arthritis Res Ther Date: 2015-09-23 Impact factor: 5.156
Authors: Cristina Fernández-Carballido; Carolina Tornero; M Carmen Castro-Villegas; Eva Galindez; José Francisco García-Llorente; María Luz García-Vivar; Beatriz Joven-Ibáñez; Xavier Juanola; Claudia Urrego-Laurín; Clementina López-Medina; Raquel Almodovar; Nieves Martínez-Alberola; Teresa Ruiz-Jimeno; Eugenio de Miguel Journal: RMD Open Date: 2020-09